A pilot study of interferon-alpha-2B dose reduction with dose optimization.

Trial Profile

A pilot study of interferon-alpha-2B dose reduction with dose optimization.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 May 2016

At a glance

  • Drugs Interferon alpha-2b (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results (10 MU/m2 and 4 MU/m2 dosing levels) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 07 Apr 2015 Planned primary completion date changed from 1 Jan 2014 to 1 Jan 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top